Jim Simons was (and is still even after his death in May 2024) one of the most important names, if not the largest, of the coverage bottom space. He was a mathematician endowed and had a successful career in the academic field before making a daring pivot to finance in the late 1970’s.
In 1978, he founded MONEMETRICS (a currency trade company) and Limroy (a coverage fund), which collapsed in an entity in 1982 and renamed Renaissance Technologies. This entity had an important goal: to use quantitative and computer -based models to exploit market inefficiencies. In other words, Simons and his team pledged to make investment decisions based on sophisticated algorithms.
Renaissance technologies (Rentech) started as a coverage background, but then became a bigger thing. It is now an investment management company that operates various coverage funds. Its emblematic offer is the Medallion Fund. The Medallion Fund is known for extraordinary returns. During the fall of dot.com (early 2000’s) and the financial crisis (2007-2011), medallion returns were 56.6% and 74.6%, respectively. After the first two years of operation, the lowest annual performance was 31.5%.
The trajectory of the medallion fund in the market and, by extension, Rentecch’s, gained a lot of money in Simons. On the death, $ 31.4 billion was worth it and ranked among the 100 best rich people in the world. And, as Simons often said, all the success he had in the market refers to the love of mathematics. Consequently, the Medallion Fund has been capable of extraordinary returns mainly because the investment team, led by Simons, leveraged mathematics.
The fund uses algorithm -based methods to identify patterns and take advantage of past data for investment decisions. That is why Rench invested (and continues to invest) billions in intellectuals and professionals in fields such as mathematics, computer science and physics. In one of his last interviews, he said: “We hired statistical, physical, astronomers, mathematicians; the important thing was that they were very smart.”
Jim Simons was a generational talent when investing. He started an investment business and caused others that others could only dream. And because his legacy lives at Rentecch, it makes sense to want to know which companies are invested.
We deepened the Renaissance Technologies’ Q4 2024 Sec 13F files to collect this list. We focused only on companies’ actions and excluded interests in ETF and options. We then chose shares with market capitalization of $ 10 billion or less. From the result, the actions based on analysts’ price goals were classified and we selected the 10 best companies with the most potential on the reverse (from April 30).
Why are we interested in the stocks that cover the funds? The reason is simple: our research has shown that we can overcome the market by imitating the best stock options for the best coverage funds. The strategy of our quarterly bulletin selects 14 stocks of small layers and large layers each quarter and has returned 373.4% since May 2014, surpassing its reference point at 218 percentage points (Check out more details here)).
Alkermes PLC (Alks): Between the billionaire Jim Simons’s Rentech’s Small Cap Stock is chosen with great potential upside down
A pharmacist who gives someone a recipe bottle containing the company’s biopharmaceutical product.
Alkermes PLC (NASDAQ: Alks) is a biopharmaceutical company based in Ireland. Develops and manufactures medicines for mental health, neurological conditions and cancer. Its key products include treatments for alcohol and opioid dependency (such as Vivitrol®), schizophrenia (Aristda® and Lybalvi®) and bipolar I.
In the fourth quarter and the financial results of the fourth quarter of 2024, Alkermes (Nasdaq: Alks) reported total revenue of $ 1.56 billion per year. Clean sales of proprietary product increased approximately 18% year -on -year to $ 1.08 million. The company registered $ 372 million in Net GAAP income for continuous operations and diluted gains per $ 2.20 ACTION (EPS). Above all, Vivitrol revenue grew by 31% (up to $ 134.1) in the quarter compared to the same period in 2023. At the same time, Lybalvi’s revenue increased by 37% to $ 77.0 million during the quarter.
These strong financial results align with increasing opportunities in the addiction treatment space. A recent Harris Poll survey commissioned by Alkermes (NASDAQ: Alks) revealed that 83% of alcohol consumption disorder respondents (AUD) agreed that it is difficult to treat/manage AC only by will. This highlights the importance of medical interventions. In addition, market research indicates that the global detox market market was evaluated at $ 66.23 billion by 2024 and is expected to grow in a CAGR of 6.3% until 2030. On April 28, 2025, UBS reviewed its price goal for Alkermes (NASDAQ) from $ 38 to $ 33, maintaining a neutral rating. The firm cited a smoother Q1 orientation and the intended market dynamics related to the next data releases related to orexin in the last half of 2025.
Overall, Alks occupies 9th place In our list of Rentecch actions, the Rentecch billionaire, wash actions with great potential on the reverse. Although we recognize the potential of the Alk as an investment, our conviction lies in the belief that the actions of the AI have a greater promise to obtain higher yields and to do it in a shorter period. There is an AI stock that increased since the beginning of 2025, while the popular AI actions lost around 25%. If you are looking for an Ia stock that is more promising than Alks, but selling less than five times, see our report on this Stock of AI cheap.
